Avantor Q3 net sales $1.71B (-0.3%), net income $57.8M, raises FCF guidance

Avantor, Inc.

2024-Q3 EPS reported $0.31 revenue$5,097,000,000

Net sales $1,714.4M, down 0.3% reported; organic decline 0.7%; currency tailwind of 0.4%.
GAAP diluted EPS $0.08; adjusted EPS $0.26; adjusted EBITDA $302.5M (17.6% margin).
Lab Solutions sales +1.1% reported (+0.6% organic); Bioscience Production -3.2% (-3.5% organic).
Operating cash flow $244.8M; free cash flow $204.0M; management raised full-year FCF guidance.
Adjusted net leverage 3.8x; bioprocessing outperformance and cost programs ahead of plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.